Clinical Trials Logo

Filter by:
NCT ID: NCT01418937 Completed - Clinical trials for Infections, Papillomavirus

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Start date: May 29, 2012
Phase: Phase 3
Study type: Interventional

This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741) study.

NCT ID: NCT01416545 Completed - Risk Reduction Clinical Trials

Children Education and Cardiovascular Risk Reduction in Their Parents

CETICARP
Start date: January 2010
Phase: N/A
Study type: Interventional

This study aims to evaluate if a multidisciplinary educational program in primary cardiovascular prevention for children could improve the Framingham Score index of their parents after one year.

NCT ID: NCT01416519 Completed - Pneumonia Clinical Trials

Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation

Start date: September 2011
Phase: N/A
Study type: Interventional

The objective of this study is to assess whether there is a difference between a care protocol with the use of incentive spirometry (Voldyne ®) and another with the application of NIV (non invasive ventilation with single-level pressure) as a form of therapy. The main focus of the study is to determine the incidence of pulmonary complications in each technique.

NCT ID: NCT01415427 Completed - MPS IVA Clinical Trials

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).

NCT ID: NCT01414465 Completed - Overweight Clinical Trials

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females

Start date: October 2009
Phase: N/A
Study type: Interventional

Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not been described yet. The FA composition of RBCs, plasma and platelets can be used to monitor of many pathological processes. This study presents alteration of FA composition in RBCM and phospholipids, triglycerides and cholesteryl esters from plasma of health obese female volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months.

NCT ID: NCT01414374 Completed - Clinical trials for Iron Deficiency Anemia

Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency

Start date: January 2012
Phase: Phase 3
Study type: Interventional

The study aims to investigate the prevalence of genetic polymorphisms in adults with iron deficiency and anemia, and the responses to two different treatments: iron sulphate and a composite herbal medicine (Hibiscus sabdariffa plus Centella asiatica). The main outcome will be hemoglobin, measured before and after 6 weeks.

NCT ID: NCT01413126 Completed - Clinical trials for Type 2 Diabetes Mellitus

Peanuts Second Meal Glycemic Response

Start date: October 2009
Phase: N/A
Study type: Interventional

Nut consumption is associated with reduced risk of Type 2 diabetes. The aim of this study was to assess the effects of peanut (whole or peanut butter) to breakfast meals on glycemic, insulinemic and selected gut hormone responses, appetite, and food intake over two consecutive meals in obese women with high Type 2 diabetes risk. Fifteen women participated in a randomized crossover trial where 42.5g of whole peanuts (P), peanut butter (PB), or no peanuts (control-C) were added to a 75g available carbohydrate-matched breakfast meal. Postprandial concentrations of blood glucose, insulin, non-esterified free fatty acids (NEFA), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), appetitive sensations and food intake were assessed after breakfast treatments and a standard lunch (75g available carbohydrate).

NCT ID: NCT01412333 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Start date: September 20, 2011
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).

NCT ID: NCT01411969 Completed - Nasal Obstruction Clinical Trials

Impact of External Nasal Dilator on the Rhinogram

ARENDS
Start date: June 2010
Phase: N/A
Study type: Observational

The aim of this study is to present new data for a better understanding of the anatomic correlation of these two notches. This study included 32 nasal cavities (16 individuals) with external nasal dilator strip (Breath Right®) and after decongestion (0.05% oxymetazoline chloride applied as an aerosol spray);

NCT ID: NCT01411683 Completed - Edentulous Jaw Clinical Trials

Mandibular Overdentures Retained by Conventional or Mini Implants

Start date: September 2011
Phase: N/A
Study type: Interventional

This study aims to compare mandibular overdentures retained either by mini or standard size implants as a treatment for edentulous adults, in terms of patient-reported satisfaction and oral health-related quality of life. We will also evaluate post surgical discomfort, the success rate of prostheses and implants in the long term, denture quality and costs.